Short-term outcomes in patients with acute coronary syndrome treated with direct bioresorbable scaffold deployment

- Limited evidence for use of bioresorbable vascular scaffold (BVS) in ACS patients.
- Eight patients had acute STEMI and underwent primary PCI with BVS.
- No cases of worsening flow, scaffold thrombosis, TLR or death to 30 days post PCI.
- Direct BVS deployment in ACS appears safe and feasible.

BackgroundDirect coronary stenting is a validated therapeutic option for coronary lesions. We studied the feasibility of direct deployment with a bioresorbable vascular scaffold (BVS) in acute coronary syndrome (ACS).MethodsDemographic, procedural, and survival data were obtained for patients who had direct scaffold deployment with BVS from 1 May 2013 to 1 April 2014.ResultsWe performed a retrospective review of nine patients which included eight patients having ST-elevation myocardial infarction. There were no cases of worsening coronary flow, scaffold thrombosis, target lesion revascularization or death up to 30 days post intervention.ConclusionDirect BVS deployment in ACS appears safe and feasible.